# Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)

> **NCT03167619** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 45 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** Olaparib Oral Product
- **DRUG:** Olaparib Oral Product in combination with Durvalumab

## Key facts

- **NCT ID:** NCT03167619
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-04
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03167619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03167619, "Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03167619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*